lactic acid has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 21 studies
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "However, triple negative breast cancers (TNBC) exhibit remarkable resistance to most therapies, including RT." | 1.51 | PK-M2-mediated metabolic changes in breast cancer cells induced by ionizing radiation. ( Alli, C; Bailleul, J; Bhat, K; Dao, A; Dong, K; Dratver, MB; Duhachek-Muggy, S; Gosa, L; Nathanson, D; Pajonk, F; Sung, D; Vlashi, E; Yazal, T; Zhang, L, 2019) |
| "Effective therapeutics against triple negative breast cancer (TNBC), which has no standard-of-care therapy, needs to be developed urgently." | 1.42 | "Triple-punch" strategy for triple negative breast cancer therapy with minimized drug dosage and improved antitumor efficacy. ( Ding, Y; Ji, T; Li, Y; Nie, G; Su, S; Tian, Y; Wu, M; Wu, Y, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 13 (61.90) | 24.3611 |
| 2020's | 8 (38.10) | 2.80 |
| Authors | Studies |
|---|---|
| Mazzio, E | 1 |
| Mack, N | 1 |
| Badisa, RB | 1 |
| Soliman, KFA | 1 |
| Cromwell, EF | 1 |
| Sirenko, O | 1 |
| Nikolov, E | 1 |
| Hammer, M | 1 |
| Brock, CK | 1 |
| Matossian, MD | 1 |
| Alzoubi, MS | 1 |
| Collins-Burow, BM | 1 |
| Burow, ME | 1 |
| Padilla, J | 1 |
| Lee, BS | 1 |
| Zhai, K | 1 |
| Rentz, B | 1 |
| Bobo, T | 1 |
| Dowling, NM | 1 |
| Lee, J | 1 |
| Guo, S | 1 |
| Zhou, J | 1 |
| Lou, P | 1 |
| Weng, L | 1 |
| Ye, X | 1 |
| Guo, J | 1 |
| Liu, H | 1 |
| Ma, R | 1 |
| Kouril, T | 1 |
| October, C | 1 |
| Hollocks, S | 1 |
| Odendaal, C | 1 |
| van Niekerk, DD | 1 |
| Snoep, JL | 1 |
| Tailor, D | 1 |
| Going, CC | 1 |
| Resendez, A | 1 |
| Kumar, V | 1 |
| Nambiar, DK | 1 |
| Li, Y | 2 |
| Dheeraj, A | 1 |
| LaGory, EL | 1 |
| Ghoochani, A | 1 |
| Birk, AM | 1 |
| Stoyanova, T | 1 |
| Ye, J | 1 |
| Giaccia, AJ | 1 |
| Le, QT | 1 |
| Singh, RP | 1 |
| Sledge, GW | 1 |
| Pitteri, SJ | 1 |
| Malhotra, SV | 1 |
| Daud, SM | 1 |
| Yaacob, NS | 1 |
| Fauzi, AN | 1 |
| Ghergurovich, JM | 1 |
| Lang, JD | 1 |
| Levin, MK | 1 |
| Briones, N | 1 |
| Facista, SJ | 1 |
| Mueller, C | 1 |
| Cowan, AJ | 1 |
| McBride, MJ | 1 |
| Rodriguez, ESR | 1 |
| Killian, A | 1 |
| Dao, T | 1 |
| Lamont, J | 1 |
| Barron, A | 1 |
| Su, X | 1 |
| Hendricks, WPD | 1 |
| Espina, V | 1 |
| Von Hoff, DD | 1 |
| O'Shaughnessy, J | 1 |
| Rabinowitz, JD | 1 |
| Amoozgar, Z | 1 |
| Goldberg, MS | 1 |
| Cerqueira, BBS | 1 |
| Lasham, A | 1 |
| Shelling, AN | 1 |
| Al-Kassas, R | 1 |
| Meena, R | 1 |
| Kumar, S | 1 |
| Kumar, R | 1 |
| Gaharwar, US | 1 |
| Rajamani, P | 1 |
| Wang, S | 2 |
| Shao, M | 1 |
| Zhong, Z | 1 |
| Wang, A | 1 |
| Cao, J | 1 |
| Lu, Y | 1 |
| Wang, Y | 2 |
| Zhang, J | 2 |
| Romero-Cordoba, SL | 1 |
| Rodriguez-Cuevas, S | 1 |
| Bautista-Pina, V | 1 |
| Maffuz-Aziz, A | 1 |
| D'Ippolito, E | 1 |
| Cosentino, G | 1 |
| Baroni, S | 1 |
| Iorio, MV | 1 |
| Hidalgo-Miranda, A | 1 |
| Zhang, L | 1 |
| Bailleul, J | 1 |
| Yazal, T | 1 |
| Dong, K | 1 |
| Sung, D | 1 |
| Dao, A | 1 |
| Gosa, L | 1 |
| Nathanson, D | 1 |
| Bhat, K | 1 |
| Duhachek-Muggy, S | 1 |
| Alli, C | 1 |
| Dratver, MB | 1 |
| Pajonk, F | 1 |
| Vlashi, E | 1 |
| Pelicano, H | 1 |
| Zhang, W | 1 |
| Liu, J | 1 |
| Hammoudi, N | 1 |
| Dai, J | 1 |
| Xu, RH | 1 |
| Pusztai, L | 1 |
| Huang, P | 1 |
| Su, S | 1 |
| Tian, Y | 1 |
| Ding, Y | 1 |
| Ji, T | 1 |
| Wu, M | 1 |
| Wu, Y | 1 |
| Nie, G | 1 |
| Chen, M | 1 |
| Bhargava-Shah, A | 1 |
| Foygel, K | 1 |
| Devulapally, R | 1 |
| Paulmurugan, R | 1 |
| Munthe, E | 1 |
| Riss, PJ | 1 |
| Saga, TA | 1 |
| Haraldsen, I | 1 |
| Grad, I | 1 |
| Bogsrud, TV | 1 |
| Bach-Gansmo, T | 1 |
| Scott, B | 1 |
| Shen, J | 1 |
| Nizzero, S | 1 |
| Boom, K | 1 |
| Persano, S | 1 |
| Mi, Y | 1 |
| Liu, X | 1 |
| Zhao, Y | 1 |
| Blanco, E | 1 |
| Shen, H | 1 |
| Ferrari, M | 1 |
| Wolfram, J | 1 |
| Bowerman, CJ | 1 |
| Byrne, JD | 1 |
| Chu, KS | 1 |
| Schorzman, AN | 1 |
| Keeler, AW | 1 |
| Sherwood, CA | 1 |
| Perry, JL | 1 |
| Luft, JC | 1 |
| Darr, DB | 1 |
| Deal, AM | 1 |
| Napier, ME | 1 |
| Zamboni, WC | 1 |
| Sharpless, NE | 1 |
| Perou, CM | 1 |
| DeSimone, JM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pilot Study To Investigate Targetable Metabolic Pathways Sustaining Triple Negative (TN) Breast Cancer and Associated Genomic Alterations[NCT03457779] | 16 participants (Actual) | Interventional | 2018-02-08 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for lactic acid and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Local production of lactate, ribose phosphate, and amino acids within human triple-negative breast cancer.
Topics: Amino Acids; Carcinoma, Non-Small-Cell Lung; Glucose; Humans; Lactic Acid; Lung Neoplasms; Proteomic | 2021 |
20 other studies available for lactic acid and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Triple Isozyme Lactic Acid Dehydrogenase Inhibition in Fully Viable MDA-MB-231 Cells Induces Cytostatic Effects That Are Not Reversed by Exogenous Lactic Acid.
Topics: Cell Cycle; Cell Line, Tumor; Cell Survival; Cytostatic Agents; Gene Expression Profiling; Gene Expr | 2021 |
Multifunctional profiling of triple-negative breast cancer patient-derived tumoroids for disease modeling.
Topics: Antineoplastic Agents; Cadherins; Humans; Lactic Acid; Triple Negative Breast Neoplasms | 2022 |
A Heme-Binding Transcription Factor BACH1 Regulates Lactate Catabolism Suggesting a Combined Therapy for Triple-Negative Breast Cancer.
Topics: Basic-Leucine Zipper Transcription Factors; Heme; Humans; Lactic Acid; Monocarboxylic Acid Transport | 2022 |
Potentiated effects of lactate receptor GPR81 on immune microenvironment in breast cancer.
Topics: B7-H1 Antigen; Carrier Proteins; Cell Line, Tumor; Cytokines; Humans; Lactic Acid; Receptors, G-Prot | 2023 |
Inhibitor titrations reveal low control of glyceraldehyde 3-phosphate dehydrogenase and high control of hexokinase on glycolytic flux in an aggressive triple-negative breast cancer cell line.
Topics: Cell Line; Glycolysis; Hexokinase; Humans; Lactic Acid; Triple Negative Breast Neoplasms | 2023 |
Novel Aza-podophyllotoxin derivative induces oxidative phosphorylation and cell death via AMPK activation in triple-negative breast cancer.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Death; Ce | 2021 |
2-Methoxy-1,4-Naphthoquinone (MNQ) Inhibits Glucose Uptake and Lactate Production in Triple-Negative Breast Cancer Cells.
Topics: Antineoplastic Agents; Cell Survival; Female; Glucose; Glycolysis; Humans; Lactic Acid; Naphthoquino | 2021 |
Surface modulation of polymeric nanocarriers enhances the stability and delivery of proteins and small molecules.
Topics: Animals; Antineoplastic Agents; CD3 Complex; Cell Line, Tumor; Cell Proliferation; Cell Survival; Ch | 2017 |
Development of biodegradable PLGA nanoparticles surface engineered with hyaluronic acid for targeted delivery of paclitaxel to triple negative breast cancer cells.
Topics: Cell Line, Tumor; Drug Carriers; Humans; Hyaluronic Acid; Lactic Acid; Nanoparticles; Paclitaxel; Po | 2017 |
PLGA-CTAB curcumin nanoparticles: Fabrication, characterization and molecular basis of anticancer activity in triple negative breast cancer cell lines (MDA-MB-231 cells).
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cetrimonium; Cetrimonium Compounds; | 2017 |
Co-delivery of gambogic acid and TRAIL plasmid by hyaluronic acid grafted PEI-PLGA nanoparticles for the treatment of triple negative breast cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Carriers; Humans; Hyaluronan Receptors; Hyalu | 2017 |
Loss of function of miR-342-3p results in MCT1 over-expression and contributes to oncogenic metabolic reprogramming in triple negative breast cancer.
Topics: Carcinogenesis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Gene Expression | 2018 |
PK-M2-mediated metabolic changes in breast cancer cells induced by ionizing radiation.
Topics: Carrier Proteins; Cell Line, Tumor; Cell Nucleus; Female; Gene Expression Regulation, Neoplastic; Gl | 2019 |
Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potential.
Topics: Adenosine Triphosphate; Cell Line, Tumor; Electron Transport Chain Complex Proteins; Energy Metaboli | 2014 |
"Triple-punch" strategy for triple negative breast cancer therapy with minimized drug dosage and improved antitumor efficacy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Carriers; Endocytosis; Female; Humans; Indocy | 2015 |
Hyaluronic acid-coated PEI-PLGA nanoparticles mediated co-delivery of doxorubicin and miR-542-3p for triple negative breast cancer therapy.
Topics: Antibiotics, Antineoplastic; Apoptosis; Breast; Cell Line, Tumor; Doxorubicin; Drug Carriers; Female | 2016 |
Orlistat and antisense-miRNA-loaded PLGA-PEG nanoparticles for enhanced triple negative breast cancer therapy.
Topics: Female; Humans; Lactic Acid; Lactones; Orlistat; Polyethylene Glycols; Polyglycolic Acid; Polylactic | 2016 |
FDG-based quantitative comparison of glucose metabolism in vitro, exemplified by a head-to-head comparison between a triple-negative breast cancer cell line and a non-malignant foetal cell line.
Topics: Adenosine Triphosphate; Cell Line, Tumor; Cell Proliferation; Culture Media, Conditioned; Energy Met | 2018 |
A pyruvate decarboxylase-mediated therapeutic strategy for mimicking yeast metabolism in cancer cells.
Topics: Acetaldehyde; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Compoundin | 2016 |
Docetaxel-Loaded PLGA Nanoparticles Improve Efficacy in Taxane-Resistant Triple-Negative Breast Cancer.
Topics: A549 Cells; Animals; Antineoplastic Agents; Bridged-Ring Compounds; Cell Survival; Docetaxel; Drug C | 2017 |